The finite proliferative potential of normal human cells leads to replicative cellular senescence, which is a critical barrier to tumour progression in vivo 1-3 . We show that the human p53 isoforms ∆133p53 and p53β 4 function in an endogenous regulatory mechanism for p53-mediated replicative senescence. Induced p53β and diminished ∆133p53 were associated with replicative senescence, but not oncogeneinduced senescence, in normal human fibroblasts. The replicatively senescent fibroblasts also expressed increased levels of miR-34a, a p53-induced microRNA 5-9 , the antisense inhibition of which delayed the onset of replicative senescence. The siRNA (short interfering RNA)-mediated knockdown of endogenous ∆133p53 induced cellular senescence, which was attributed to the regulation of p21 WAF1 and other p53 transcriptional target genes. In overexpression experiments, whereas p53β cooperated with full-length p53 to accelerate cellular senescence, ∆133p53 repressed miR-34a expression and extended the cellular replicative lifespan, providing a functional connection of this microRNA to the p53 isoformmediated regulation of senescence. The senescence-associated signature of p53 isoform expression (that is, elevated p53β and reduced ∆133p53) was observed in vivo in colon adenomas with senescent phenotypes 10,11 . The increased ∆133p53 and decreased p53β isoform expression found in colon carcinoma may signal an escape from the senescence barrier during the progression from adenoma to carcinoma.
Normal human somatic cells can undergo a limited number of cell divisions, eventually reaching an irreversible proliferation arrest known as replicative cellular senescence 2, 12 . Various cellular stresses (for example, oncogene activation and DNA damage) can also induce cellular senescence [1] [2] [3] . Whether replicatively induced or prematurely stress-induced, cellular senescence constitutes a critical mechanism for tumour suppression in vivo and may contribute to organismal ageing [1] [2] [3] . The p53 signalling pathway has a central role in the regulation of cellular senescence 2, 3 . Drosophila, zebrafish and humans are reported to have p53 isoforms 4, 13 ; however, their regulation and function are poorly understood. Here, we examine the expression profiles of two human p53 isoforms, p53β (which lacks the carboxy-terminal oligomerization domain due to alternative mRNA splicing) 4 and ∆133p53 (which lacks the amino-terminal transactivation and proline-rich domains due to the transcription from an alternative promoter in intron 4; ref. 4) , during cellular senescence in vitro and in vivo, their biological activities in regulating cellular senescence and the physiological role of miR-34a (refs 5-9) in p53-mediated senescence.
By using the p53β-specific antibody TLQ40 (ref. 4 ) and the Δ133p53-specific antibody MAP4 (Fig. 1a) , the endogenous expression levels of p53β and Δ133p53 were examined in normal human fibroblast strains (MRC-5 and WI-38) at early passage (both strains at passage number 30, Y in Fig. 1b ) and at replicative senescence (MRC-5 at passage 65 and WI-38 at passage 58, S in Fig. 1b; Supplementary Information, Fig. S1a ). Whereas expression of full-length p53 (detected by showed no changes during replicative senescence, p53β was specifically detected when cells became senescent. In remarkable contrast, expression of Δ133p53 was markedly diminished in senescent cells. As reported previously 14 , increased amounts of p53 phosphorylated at Ser 15 (pS15-p53) were associated with replicative senescence (Fig. 1b) . Use of a CM1 antibody (which detects p53, p53β and ∆133p53) showed that p53β and Δ133p53 were expressed less abundantly than full-length p53 but still at readily detectable levels (Fig. 1b) . Premature senescence induced by oncogenic Ras ( Supplementary Information, Fig. S1b ) or acute telomere dysfunction (by knockdown of POT1, ref. 15 , or overexpression of a dominant-negative TRF2 mutant 16 ) was not associated with either induced p53β or diminished Δ133p53 (Fig. 1c-e) .
L E T T E R S
In addition to upregulated p21 WAF1 (Fig. 1b ) 17, 18 , the MRC-5 and WI-38 fibroblasts expressed increased amounts of miR-34a at replicative senescence (Fig. 2a) , a microRNA that is transactivated by full-length p53 ( Supplementary Information, Fig. S2a , b) and can induce cellular senescence when overexpressed [5] [6] [7] [8] [9] . A locked nucleic acids (LNA)-antisense oligonucleotide was used to specifically knockdown the endogenous expression of miR-34a. The specific effect of the LNA antisense was demonstrated by diminished levels of miR-34a in a quantitative reverse transcription-PCR (qRT-PCR) assay (Fig. 2b) , increased amounts of SIRT1 and E2F1 (which were previously reported to be downregulated by miR-34a; Fig. 2c ) 9, 19 and the abrogation of a miR-34a binding sitedependent decreased activity in a luciferase reporter assay (Fig. 2d ) 20 . The antisense inhibition of miR-34a in late-passage MRC-5 fibroblasts resulted in an extension of the replicative lifespan by approximately three population doublings (PDLs; Fig. 2e ). The lifespan extension by miR-34a inhibition was reproducibly observed in an independent experiment using an antisense 2-O-methyl oligonucleotide (Fig. 2f, g ). Nutlin-3a-induced senescence, which is dependent on the accumulation and activation of endogenous p53 (ref. 21) , was also significantly, but partially (by approximately 50%), inhibited by the 2-O-methyl oligonucleotidemediated knockdown of endogenous miR-34a (Fig. 2h) . These findings provide the first evidence that endogenous levels of miR-34a, one of the downstream effectors of the p53 signalling pathway, have a physiological role in cellular senescence.
The endogenous expression of Δ133p53 was knocked down by RNA interference (RNAi) in early-passage WI-38 ( 16 . Early-passage MRC-5 and WI-38 (at passage 32) cells were used. H1299 cells overexpressing p53β were used as the positive control for p53β. Vec, vector control. β-actin was used as a loading control.
Δ133p53 with a minimal effect on full-length p53 and no induction of p53β ( Fig. 3a; Supplementary Information, Fig. S3a ). Cells transfected with Δ133si-1 and Δ133si-2 underwent a rapid and uniform senescent growth arrest (within 7 days), showing a flattened cell morphology ( Fig. 3b ; Supplementary Information, Fig. S3b ), the induction of senescenceassociated β-galactosidase (SA-β-gal) activity (Fig. 3b, c ; Supplementary   Information, Fig. S3b ) and the attenuation of BrdU (bromo-deoxyuridine) incorporation ( Fig. 3d; Supplementary Information, Fig. S3c ). These results suggest that the endogenous expression of Δ133p53 is critical for the replicative potential of normal human fibroblasts. The Δ133p53 knockdowninduced senescence was accompanied by upregulation of p21 WAF1 ( Fig. 3a;  Supplementary Information, Fig. S3a) . Also examined by qRT-PCR were , and pRL-SV40 (control plasmid for normalization) were co-transfected with LNA-anti-mir-34a (+) or control oligonucleotide (-).
Normalized luciferase activities are shown relative to the value obtained with pMIR-MYCN-MT1&2 (-) and control oligonucleotide (-). Data are the mean from triplicate samples. (e) The transfection of LNA-anti-mir-34a or control oligonucleotide was repeated every 4 days and the cumulative population doubling (PDL) was examined. Two independent experiments gave reproducible results in b-e. (f-h) Antisense knockdown of miR-34a by 2´-O-methyl oligonucleotides. Late-passage MRC-5 fibroblasts (at passage 58) were transfected with an antisense 2´-O-methyl oligonucleotide against mir-34a or a control oligonucleotide (against enhanced green fluorescence protein, EGFP) and analysed by real-time qRT-PCR assays of miR-34a (f; left) and miR-34b (right). A non-specific effect on miR-34b was not observed. Data are mean ± s.d. from three independent transfections. The oligonucleotide transfection was repeated every 4 days and the cumulative PDL (g) was examined, as in e. hTERT-immortalized human fibroblasts (hTERT/NHF) were transfected with the 2´-O-methyl oligonucleotides (mir-34a antisense or control) and induced to senesce by treatment with Nutlin-3a (10 μM) for 72 h (ref. 21) . A summary of senescence-associated β-galactosidase (SA-β-gal) assay is shown (h). Data are mean ± s.d. from three independent experiments in h, *P < 0.05. 25 and CDC20 (cell-division cycle 20 homologue) 26 have been reported to be upregulated (the former three) or downregulated (the latter two) at cellular senescence 27 and predicted (IGFBP7; www2.ba.itb.cnr.it/p53FamTaG) or experimentally shown (the other four) to be transcriptionally regulated by p53 (refs 22, 25-27) . The corresponding genes were examined by qRT-PCR and found to have altered expression of the expected type (Fig. 3e) , consistent with activation of full-length p53 on relief from the dominantnegative inhibition by Δ133p53 (ref. 4) . Unlike at replicative senescence, however, miR-34a was not upregulated at Δ133p53 knockdown-induced senescence ( Supplementary Information, Fig. S2c ). Two proapoptotic p53 target genes, PUMA and BAX, were not upregulated either (data not shown) and consistently, immunoblot analyses of poly(ADP-ribose) polymerase (PARP) or caspase-3 did not show signs of apoptosis in these siRNA-transfected fibroblasts ( Supplementary Information, Fig. S3d ).
PAI
Flag-tagged p53β or Δ133p53 were retrovirally expressed in earlypassage WI-38 and MRC-5 human fibroblasts ( Supplementary  Information, Fig. S4a ). p53β inhibited cell proliferation (Fig. 4b ) and induced cellular senescence (Fig. 4c) . p53β overexpression also upregulated p21 WAF1 and MDM2 (Fig. 4a ) 28 , as reported previously 4 , but not miR-34a ( Supplementary Information, Fig. S2c ). Among the p53 target genes that were regulated by Δ133p53 knockdown, in p53β-overexpressing fibroblasts MMP3 was similarly upregulated, BUB1 and CDC20 were downregulated to a lesser degree and PAI-1 and IGFBP7 did not show a consistent change ( Supplementary Information, Fig. S4 ). p53β also inhibited cell proliferation and induced cellular senescence in a telomerase-immortalized fibroblast cell line ( Supplementary  Information, Fig. S5 ). However, the overexpression of p53β had no effect Full-length p53 on cell proliferation, cellular senescence or the expression of p21 WAF1 in p53-null MDAH041 fibroblasts (homozygous for a frameshift mutation at codon 184; data not shown) 29 , indicating that p53β cooperates with full-length p53. In contrast to p53β, overexpression of Δ133p53 in earlypassage MRC-5 and WI-38 fibroblasts (Fig. 4a ) accelerated cell proliferation ( Fig. 4b ) without inducing cellular senescence (Fig. 4c) , and repressed the expression of p21 WAF1 and MDM2 (Fig. 4a) . Consistent with its dominant-negative activity against full-length p53 (ref. 4) , the overexpression of Δ133p53 did not affect cell proliferation in p53-null MDAH041 fibroblasts (data not shown).
The biological effects of Δ133p53 were more evident when overexpressed in late-passage human fibroblasts. In MRC-5 and WI-38 cells, whereas vector control cells underwent senescent growth-arrest at only 1-5 PDLs after retroviral transduction, Δ133p53-overexpressing cells reproducibly bypassed this normal senescence point and continued to proliferate for 6-15 more PDLs ( promoter ( Supplementary Information, Fig. S2b) . Together with the extension of replicative lifespan by miR-34a knockdown (Fig. 2) , these findings suggest that the extension of replicative lifespan by Δ133p53 can be attributed, in part, to its ability to dominant-negatively inhibit p53 induction of miR-34a, and they provide a functional connection of this p53-induced microRNA to the p53 isoform-mediated regulation of replicative senescence. In Δ133p53-overexpressing cells, both the overall length of telomeres and the amount of telomeric 3 overhangs continued to be reduced beyond those in the senescent vector control cells ( Fig. 4g ; compare Δ133p53 at day 96 and vector at day 35) , indicating that the Δ133p53-induced extension of the replicative lifespan was not due to telomere stabilization.
Colon adenomas are premalignant tumours associated with telomere shortening-induced replicative senescence 30, 31 and oncogene-induced, interleukin-regulated premature senescence 10, 11, 32 .
Consistently, we observed positive SA-β-gal staining in adenoma tissues (Fig. 5a ). The expression of p16 INK4A , an in vivo senescence marker 33 , was significantly more abundant in colon adenomas than in non-adenomas or normal colon tissues ( Fig. 5b; Supplementary  Information, Fig. S7a, c) , as reported previously 10, 32 . Colon adenoma tissues expressed elevated levels of p53β and reduced levels of Δ133p53, compared with non-adenoma and normal colon tissues ( Fig. 5c, d ; Supplementary Information, Fig. S7 ). These results show that the senescence-associated p53 isoform expression signature (that is, elevated p53β and reduced Δ133p53) occurs not only in cultured cells in vitro but also in humans in vivo and in cells of different origins (that is, both mesenchymal and epithelial).
In contrast to colon adenomas, colon carcinoma tissues (Fig. 5c , bars 'Ca') did not show the senescence-associated p53 isoform expression signature; they showed Δ133p53 increased and p53β decreased back Table S3 ). The expression levels of Δ133p53 and p53β in carcinoma tissues are shown relative to those in non-carcinoma tissues. Data are mean ± s.d., *P < 0.05. The same data were analysed by paired Student's t-test in Supplementary Information, Fig. S8 . p53β was significantly less abundant in carcinoma tissues because of the marked increase in non-carcinoma tissues as shown in c. (f) IL-8 expression was examined by qRT-PCR in the same non-adenoma, adenoma, non-carcinoma and carcinoma tissues as in c. The expression levels are shown as relative log 2 values to non-adenoma (defined as 0). Data are mean ± s.d., *P < 0.05, **P < 0.001.
to levels similar to those in normal colons and non-adenoma tissues. Although the adjacent non-carcinoma tissue (Fig. 5c , bars 'Non-ca') expressed significantly elevated levels of p53β, its biological importance is currently unknown. The stage I carcinomas had already failed to maintain the characteristics of adenomas, showing significantly increased Δ133p53 and decreased p53β, compared with adenomas (Fig. 5d) . These results suggest that the loss of the senescence-associated p53 isoform expression signature may signal an escape from the senescence barrier observed in premalignant tumours 1, 3, 11, 32, 34 . A further significant increase in Δ133p53 from stage I to II and a further decrease in p53β from stage II to III (Fig. 5d) carcinomas might also have a role during stage progression. In the subgroup analysis based on p53 status, the expression levels of Δ133p53 were significantly higher in carcinoma tissues than in non-carcinoma tissues in p53 wild-type cases ( Fig. 5e; Supplementary Information, Fig. S8c ), but not in p53 mutant cases ( Supplementary Information, Fig. S8c ), in agreement with the ability of Δ133p53 to inhibit full-length p53 function. Together, our in vivo data suggest that, although mutated p53 may have a predominant role over the p53 isoforms, altered expression of these isoforms contributes to the senescence phenotype in premalignant lesions, as well as to escape from the senescence barrier and malignant progression, especially in cases without p53 gene mutations or at early carcinoma stages before the mutations occur.
Interleukin-8 (IL-8) was upregulated in colon adenoma tissues compared with adjacent non-adenoma tissues (Fig. 5f ). The IL-8 signalling pathway is involved in both replicative senescence and oncogene-induced senescence in a p53-dependent manner 34 , which are observed in colon adenomas 11, [30] [31] [32] . However, it is unlikely that this cytokine-mediated mechanism for senescence primarily regulates, or is regulated by, the senescence-associated expression signature of the p53 isoforms, because colon carcinoma tissues without such signature (Fig. 5c ) still expressed remarkably increased IL-8 levels (Fig. 5f ) and adjacent non-carcinoma tissues with elevated p53β (Fig. 5c) showed no increase in IL-8 expression (Fig. 5f ). Considering our in vitro data showing that the senescence-associated p53 isoform expression signature is observed in replicative senescence but not in oncogenic Ras-induced senescence (Fig. 1b, c) , a full malignant conversion from adenoma to carcinoma may require overcoming the senescence barriers by both p53 isoform-dependent (that is, replicative senescence) and -independent (for example, oncogene-induced, interleukin-regulated senescence) mechanisms. The lack of significant difference in p53β or Δ133p53 expression between Kiristen-Ras (K-Ras) wild-type (n = 19) and mutant (n = 4) colon carcinoma cases (data not shown) further suggests that the p53 isoforms are not primarily regulated by K-Ras. p21 WAF1 was commonly upregulated in replicative senescence (Fig. 1b) , Δ133p53 knockdown-induced senescence ( Fig. 3a; Supplementary  Information, Fig. S3a ) and p53β overexpression-induced senescence ( Fig. 4a; Supplementary Information, Fig S5b) . Whereas MMP3 was similarly upregulated at both Δ133p53 knockdown-and p53β overexpression-induced senescence, the expression profiles of the other four senescence-associated p53 target genes in these two senescence states were not generally consistent with each other (Fig. 3e; Supplementary  Information, Fig. S4 ). These findings on p53 target-gene selectivity suggest that the molecular bases of Δ133p53 knockdown-induced senescence and p53β overexpression-induced senescence are overlapping but distinct from each other. Our data suggest that the repression of miR-34a, leading to continued expression of cell-cycle progression genes [5] [6] [7] , is causally involved in a p53 inhibition-induced extension of cellular replicative lifespan (Fig. 4f) . However, the induction of senescence by either Δ133p53 knockdown or p53β overexpression occurred without upregulating miR-34a ( Supplementary Information, Fig. S2c ). We speculate that human fibroblasts may become committed to miR-34a expression only at a later stage of their replicative lifespan, when the Δ133p53 overexpression experiment was carried out. Differential levels of p53 post-translational modifications 14 , such as pS15-p53 (Fig. 1b) , and/or the concomitant occurrence of decreased Δ133p53 and increased p53β (Fig. 1b) may be involved in this commitment.
Diminished Δ133p53 protein or induced p53β protein at replicative senescence was not due to regulation at the transcriptional or mRNA splicing level ( Supplementary Information, Fig. S9a ). Treatment with a proteasome inhibitor, MG132, showed that full-length p53 and p53β, but not Δ133p53, were subject to proteasomal degradation ( Supplementary Information, Fig. S9b ). Overexpressed full-length p53 led to upregulated p53β and downregulated Δ133p53 ( Supplementary  Information, Fig. S9c ), both of which could in turn activate the function of full-length p53. The positive feedback regulation between the elevated activity of full-length p53 and upregulated p53β or downregulated Δ133p53 may be essential for the induction, maintenance and irreversibility of the senescence state of human cells. The molecular details of the protein expression and degradation of the p53 isoforms await further investigation.
In summary, based on the in vitro expression and function analyses of endogenous proteins, which are supported by the overexpression experiments, this study provides the first evidence for the physiological regulation of replicative cellular senescence by natural p53 isoforms. With in vivo evidence that the establishment and loss of the specific expression profile of the p53 isoforms constitute the induction of and escape from the senescence state, respectively, this study may open up a new p53-based, senescence-mediated strategy to manipulate carcinogenesis and ageing.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/.
Note: Supplementary Information is available on the Nature Cell Biology website.
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M E T H O D S
METHODS
Cells. CC1, a human choriocarcinoma cell line expressing Δ133p53 due to a genomic rearrangement deleting exons 2, 3 and 4 (ref. 36) , was a gift from M. Oshimura (Tottori University, Japan). Normal human fibroblast strains MRC-5, WI-38, H1299, RKO and 293T were obtained from the American Type Culture Collection (Manassas, VA, USA). hTERT/NHF, an hTERT (human telomerase reverse transcriptase)-immortalized human fibroblast cell line, was described previously 37 . The MDAH041 cell line was provided by M. Tainsky (Case Western Reserve University, OH, USA). Treatment with Nutlin-3a was as described previously 21 .
Plasmid constructs. To generate retroviral expression vectors of human p53 isoforms, Flag-tagged p53β and Flag-tagged ∆133p53 were PCR-amplified using pSVp53β and pSVDNp53 (ref. 4) , respectively, as templates and then inserted into NotI and EcoRI sites of a pQCXIN vector (BD Biosciences). Full-length p53 cDNA was similarly cloned into the same vector. These constructs were verified by DNA sequencing. The retroviral construct pLPC-Myc-TRF2 ΔBΔM was a gift from T. de Lange (Rockefeller University, NY, USA). The retroviral expression vector for H-RasV12 was a gift from M. Serrano (Spanish National Cancer Research Center). The shRNA knockdown vectors targeting p53 and POT1 were described previously 15 . The pCMVβ plasmid vector (Clontech, Mountain View, CA, USA) and its derivatives containing full-length p53 cDNA (wild type and 273H mutant) were described previously 38 . The luciferase reporter plasmids containing the mir-34a promoter fragments (wild type and mutated at the p53-binding site) 7 were provided by G. ; Sigma-Aldrich). Two days after infection, the cells were selected with G418 (600 μg ml [dT]-3´) were synthesized at Invitrogen. Both Δ133si-1 and Δ133si-2 were designed to target the sequences that are present in Δ133p53 mRNA as 5´-UTR but spliced out of full-length p53 mRNA as intron 4. The following antisense 2´-O-methyl oligonucleotides were purchased from Integrated DNA Technologies: 5´-AAC AAC CAG CUA AGA CAC UGC CA-3´ for inhibiting mir-34a; and 5´-AAG GCA AGC UGA CCC UGA AGU-3´ as a control, which is complementary to EGFP (enhanced green fluorescence protein). The LNA (locked nucleic acid) antisense oligonucleotide for mir-34a knockdown and the control oligonucleotide were purchased from Exiqon. siRNA, LNA antisense and 2´-O-methyl antisense oligonucleotides were transfected at a final concentration of 12 nM, 15 nM and 40 nM, respectively, into MRC-5 and WI-38 fibroblasts by using the Lipofectamine RNAiMAX transfection reagent (Invitrogen) according to the supplier's protocol. In experiments where cellular replicative lifespan was examined, transfection was repeated every 4 days.
Cell proliferation and senescence assays. For cell proliferation assay, 2.4 × 10 5 cells per well were plated into 12-well plates. These cells were collected and counted daily for a week using a hematocytometer. The experiments were performed at least twice and data at each time point were in triplicate. For examining cellular replicative lifespan, the number of cells was counted at each passage, and the number of PDLs achieved between passages was determined by log 2 (number of cells obtained/number of cells inoculated). SA-β-gal staining was performed as described previously 15, 21 . For the BrdU incorporation assay, cells were incubated with BrdU (10 μM) for 24 h. The incorporated BrdU was detected using an anti-BrdU monoclonal antibody (Amersham Biosciences) and observed with a fluorescent microscope. The nuclei were counterstained with DAPI (4´,6-diamidino-2-phenylindole).
Immunoblot analysis. Cells or tissues were lysed in RIPA buffer (10 mM TrisHCl at pH 7.5, 150 mM NaCl, 0.1% SDS, 0.1% sodium deoxycholate, 1 mM EDTA, 1% NP-40, complete protease inhibitors from Roche and phosphatase inhibitor cocktail 1 and 2 from Sigma-Aldrich). Following SDS-PAGE, samples were transfered to nitrocellulose or PVDF membranes (Bio-Rad), incubated with antibodies and signals were detected according to standard procedures using ECL detection (Amersham Biosciences) or SuperSignal West Dura Extended Duration system (Pierce Biotechnology). Quantitative analysis of the immunoblot data was performed using ImageJ 1.40g software (http://rsb.info.nih.gov/ij/).
Antibodies.
A polyclonal antibody specifically recognizing Δ133p53 (1:5,000; MAP4) was raised at Moravian Biotechnology in rabbits injected with a mixture of peptides, MFCQLAKTC and FCQLAKTCP, which were synthesized as a multiple antigenic peptide by G. Bloomberg (University of Bristol, UK). The other primary antibodies used were: TLQ40 ( ; SMP14 (1:1,000; Santa Cruz Biotechnology) for MDM2; 8G10 (1:1,000; Cell Signaling Technology) for caspase-3; M2 monoclonal antibody (1:10,000; Sigma-Aldrich) for Flag tag; AC-15 (1:10,000; Sigma-Aldrich) for β-actin; G175-1239 (1:1,000; BD Pharmingen) for p16
INK4a
; anti-PARP (1:1,000; Cell Signaling Technology); anti-SIRT1 (1:1,000; Santa Cruz Biotechnology) and anti-E2F1 (1:1,000; Santa Cruz Biotechnology). Horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibodies (Santa Cruz Biotechnology) were used as secondary antibodies in immunoblots.
Real-time qRT-PCR for quantification of microRNA expression. RNA samples were prepared by using Trizol (Invitrogen). Reverse transcriptase reactions were performed using TaqMan microRNA reverse transcription kit (Applied Biosystems, cat. no. 4366596) and a mir-34a-or mir-34b-specific primer. The TaqMan microRNA assay kit for mir-34a (Applied Biosystems, cat. no. 4373278) or mir-34b (Applied Biosystems, cat. no. 4373037) was used according to the supplier's protocol. Real-time PCR reactions were performed in triplicate. RNU66 (Applied Biosystems, cat. no. 4373382) was used as a control for quantification. Normalized expression of miR-34a or miR-34b was calculated by using the ΔΔCt method according to the supplier's protocol (protocol no. 4310255B and User Bulletin no. 4303859B at http://www.appliedbiosystems.com/index.cfm).
Real-time qRT-PCR for quantification of mRNA expression. For quantitative measurement of PAI-1 mRNA, SYBR Green PCR Master Mix (Applied Biosystems) was used with the following primers: 5´-CTC CTG GTT CTG CCC AAG T-3´ and 5´-CAG GTT CTC TAG GGG CTT CC-3´ for PAI-1; and 5´-TTC TGG CCT GGA GGC TAT C-3´ and 5´-TCA GGA AAT TTG ACT TTC CAT TC-3´ for β-2-microglobulin as an internal control. The Taqman Universal PCR Master Mix (Applied Biosystems) was used with the following sets of probe and primers purchased from Applied Biosystems: IGFBP7 (Hs00944483_m1); MMP3 (Hs00968308_m1); BUB1 (Hs01557701_m1); CDC20 (Hs00426680_mH); IL-8 (Hs00174103_m1) and IL-8R (Hs001174304_m1). The endogenous control was β-2-microglobulin (cat. no. 4333766). Quantitative data analysis was perfomed using the ΔΔCt method, as above.
RT-PCR for p53β and Δ133p53. The primers specifically detecting the alternative splicing that generates β isoforms were: 5´-CTT TGA GGT GCG TGT TTG TGC-3´ and 5´-TTG AAA GCT GGT CTG GTC CTG A-3´. The primers specifically amplifying Δ133p53 mRNA transcribed from the promoter in intron 4 were: 5´-TGG GTT GCA GGA GGT GCT TAC-3´ and 5´-CCA CTC GGA TAA GAT GCT GAG G-3´. The general amplification of p53 mRNA (not in an isoform-specific manner) was performed with 5´-CTC ACC ATC ATC ACA CTG GAA-3´ and 5´-TCA TTC AGC TCT CGG AAC ATC-3´. GAPDH was amplified as a control by using 5´-CCA TCT TCC AGG AGC GAG A-3´ and 5´-TGT CAT ACC AGG AAA TGA GC-3´.
Luciferase reporter assay of mir-34a-gene promoter. p53-null MDAH041 fibroblasts were retrovirally transduced with p53β, Δ133p53 or a vector control, selected for G418 resistance, plated into 24-well plates and then transfected with DOI: 10.1038/ncb1928 a full-length p53 expression plasmid (0.2 μg per well; wild type or 273H mutant) or the empty vector, together with the wild-type or mutant mir-34a promoterluciferase construct (0.3 μg per well) and of pRL-SV40 control plasmid (3 ng per well; Promega, Madison). Firefly luciferase activity (from mir-34a promoter) and Renilla luciferase activity (from pRL-SV40) were measured using the Dualluciferase Reporter system (Promega).
Luciferase reporter assay of antisense miR-34a-knockdown. MRC-5 fibroblasts on 24-well plates were transfected with pMIR-MYCN-WT or pMIR-MYCN-MT1&2 (0.3 μg per well each), LNA oligonucleotides (15 nM) and pRL-SV40 (5 ng per well; Promega) using the Lipofectamine 2000 transfection reagent (Invitrogen). Measurement of activities was performed as described above.
Measurement of telomeric 3´ overhang and telomere length. In-gel Southern hybridization, under native and denatured conditions, was performed as described previously 15 . Genomic DNA samples were digested with HinfI and electrophoresed through 0.7% agarose gel. After drying at 25°C for 30 min in a Bio-Rad model 583 gel dryer, the gel was hybridized with a 32 P-labelled [CCCTAA] 4 oligonucleotide, followed by washing and signal detection using the Typhoon 8600 system (Molecular Dynamics). The amounts of telomeric 3´ overhangs, normalized to loaded DNA detected with ethidium bromide staining of the gel, were quantified using the ImageQuant version 5.2 software (Molecular Dynamics). After alkali denaturation (0.5M NaOH/1.5M NaCl) and neutralization (2.5M NaCl/0.5M Tris-HCl at pH 7.5) of the dried gel, the same procedures were repeated to examine telomere length, which was indicated as a peak TRF (terminal restriction fragment) length. 
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Figure S1 SA-β-gal staining in replicative senescence and oncogene-induced senescence. a, MRC-5 and WI-38 fibroblasts at early passage (upper panels) and at replicative senescence (lower panels). b, MRC-5 and WI-38 retrovirally transduced with vector control (upper panels) and pBabe-Puro ras (H-RasV12) 1 (lower panels). Note that premature senescence by POT1 knockdown was induced and confirmed by SA-β-gal staining as described in our previous study 2 . The dominant-negative TRF2-induced senescence was also as previously described by us 3 Table S3 ) were examined in immunoblot for ∆133p53 expression using 16% SDS-PAGE gels (a) and p53β expression using 10% SDS-PAGE gels (b). β-actin was the control for normalization. Arrows indicate the positions of p53β bands. Normal colon, non-adenoma and/or adenoma samples were included in each blot for quantitative comparison among different blots and different histopathological types. The data shown in Fig. 5c (Non-ca and Ca), 5d (Carcinoma, stage I, II and III) and 5e, as well as in c and d below, were from the quantitative analysis of these results. c and d, Paired t-test analyses of ∆133p53 and p53β expression in p53 'wild-type' versus 'mutant' cases of colon carcinomas. Twenty-eight cases of colon carcinomas were classified into two subgroups assumedly with 'wild-type' (n = 16) and 'mutant' p53 (n = 12), based on the immunohistochemical staining of p53 and MDM2 8, 9 (Supplementary Table S3 ). In each subgroup, the expression levels of ∆133p53 (c) and p53β (d) were compared between non-carcinoma (Non-ca) and carcinoma tissues by paired t-test. The vertical axes are the expression levels normalized with β-actin. The p-values are in the parentheses. The p53 'wild-type' carcinomas, but not "mutant" carcinomas, expressed significantly higher levels of ∆133p53. p53β was significantly less abundant in carcinoma tissues in both subgroups because of the marked increase in non-carcinoma tissues (Fig. 5c) 
